* Luxabendazolum [Latin]
* 2-Benzimidazolecarbamate, 5-hydroxy-, p-fluorobenzenesulfoonate
* Methyl 5-hydroxy-2-benzimidazolecarbamate, p-fluorobenzenesulfonate (ester)
* Luxabendazole [BAN:INN] * Luxabendazol [Spanish]
* CCRIS 7645 * HOE 216V

365.337

Luxabendazole(LBZ) is a new benzimidazole carbamate chemotherapeutic agent. It binds to the structural protein tubulin, thereby preventing its polymerization to microtubules which provide the transport system for the absorbing cells. The consequence of blocking this transport activity is incomplete absorption and digestion of nutrient particles and cellular autolysis through activation of lysosomal enzymes.
Luxabendazole(LBZ) has proved to be effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes.
Based on the scientific study on the anthelmintic potential of luxabendazole (department of General Zoology and Parasitology, University of Veterinary Science, Budapest, Hungary), a single oral treatment at doses of 10.0 or 12.5 mg/kg body wt removed 97.6% of the adult Fasciola hepatica and 63.2%-83.8% of the Dicrocoelium dendriticum. Luxabendazole at 7.5, 10.0, and 12.5 mg/kg proved 100% effective in removing adult worms of the genera Haemonchus, Ostertagia, Trichostrongylus, Cooperia and Nematodirus as well as tissue-associated larval stages of gastrointestinal nematodes of the abomasal mucosa. The drug showed an intensity effect of 79.7%-87.6% against Strongyloides papillosus. Luxabendazole removed all Dictyocaulus filaria and reduced the fecal excretion of larvae of protostrongylid species (Protostrongylus rufescens, Neostrongylus linearis, Cystocaulus ocreatus, Muellerius capillaris) by 97.8%-99.6%.